CompoAtlas

Serratiopeptidase 120,000

Natural health product licensed in Canada

If this product were sold in France

No point flagged by the rules we apply.

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Medicinal ingredient and sourcePer dosage unit, according to the sourceMaximum per day, adult
Serrapeptase

Source : Serratia marcescens E-15 - Cellule Entiière

120,000 SPUNot calculated
Serrapeptase

Source : Serrapeptase

120,000 SPUNot calculated
Serrapeptase

Source : Serratia marcescens E-15 - Cellule Entiière

54.54 milligrammeNot calculated
Serrapeptase

Source : Serrapeptase

54.54 milligrammeNot calculated

Non-medicinal ingredients

Cellulose microcristalline, NA, Stéarate de magnésium, Eau purifiée

PopulationAgeQuantity per servingFrequency
Adultesminimum: 19 years1 Capsule1 Tous les jours

Uses authorised in Canada

Proteolytic Enzyme. Helps to reduce (symptoms such as) pain, quantity of secretion, inability to perceive smell and stuffy nose from ear, nose and/or throat infections. Mucolytic enzyme that helps break down mucous. Helps reduce and/or relieve postoperative cheek swelling and/or pain after dental surgery.

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

Product record

Other names
Serrapeptase, Serrapeptase 120,000, Serrapeptase 120K, Serrapeptase Double Strength, Serratiopeptidase, Serratiopeptidase 120K, Serratiopeptidase Double Strength, Webber Naturals Serrapeptase, Webber Naturals Serrapeptase 120,000, Webber Naturals Serrapeptase 120K, Webber Naturals Serrapeptase Double Strength, Webber Naturals Serratiopeptidase, Webber Naturals Serratiopeptidase 120,000, Webber Naturals Serratiopeptidase 120K, Webber Naturals Serratiopeptidase Double Strength
Licence holder
WN Pharmaceuticals Ltd
NPN or DIN-HM
80079432
Status
Active licence
Licence date
14 August 2017
Revision date
Not provided
Form
Capsule, libération-retardée
Route of administration
Orale
Application type
Officinale

Source

Official Health Canada record, licence 80079432

Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Serrapeptase
    Read the warning, when it applies and the studies cited

    SERRAPEPTASE

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have gastrointestinal lesions/ulcers, a kidney or liver disorder, or are having surgery (Bhagat et al. 2013; Chopra et al. 2009; Al- Khateeb and Nusair 2008; Mazzone et al. 1990).

    Sources cited by Health Canada (4)
    • Bhagat S, Agarwal M and Roy V. Serratiopeptidase : A systemic review of the existing evidence. International Journal of Surgery 2013;11(3):209-217 PubMed Systematic review
    • Chopra D, Rehan HS, Mehra P, et al. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of paracetamol, serratiopeptidase, ibuprofen and betamethasone using the dental impaction pain model. International Journal of Oral Maxillofacial Surgery 2009;38:350-355. PubMed Randomised trial
    • Mazzone A, Catalani M, Costanzo M, et al. Evaluation of serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology : a multicentre, double-blind, randomized trial versus placebo. Journal of International Medical Research 1990;18:379-388. PubMed Randomised trial
    • Al-Khateeb TH and Nusair Y. Effect of the proteolytic enzyme serrapeptase on swelling, pain and trismus after surgical extraction of mandibular third molars. International Journal of Oral Maxillofacial Surgery 2008;37:264-268. PubMed Randomised trial

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners or anti-inflammatory medications (Bhagat et al. 2013; Chopra et al. 2009; Al-Khateeb and Nusair 2008; Mazzone et al. 1990).

    Sources cited by Health Canada (4)
    • Al-Khateeb TH and Nusair Y. Effect of the proteolytic enzyme serrapeptase on swelling, pain and trismus after surgical extraction of mandibular third molars. International Journal of Oral Maxillofacial Surgery 2008;37:264-268. PubMed Randomised trial
    • Bhagat S, Agarwal M and Roy V. Serratiopeptidase : A systemic review of the existing evidence. International Journal of Surgery 2013;11(3):209-217 PubMed Systematic review
    • Chopra D, Rehan HS, Mehra P, et al. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of paracetamol, serratiopeptidase, ibuprofen and betamethasone using the dental impaction pain model. International Journal of Oral Maxillofacial Surgery 2009;38:350-355. PubMed Randomised trial
    • Mazzone A, Catalani M, Costanzo M, et al. Evaluation of serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology : a multicentre, double-blind, randomized trial versus placebo. Journal of International Medical Research 1990;18:379-388. PubMed Randomised trial

    Known adverse reactions

    Stop use if rash, difficulty breathing, hypersensitivity and/or severe allergy occur (Bhagat et al. 2013; Balagi 2007).

    Sources cited by Health Canada (1)
    • Bhagat S, Agarwal M and Roy V. Serratiopeptidase : A systemic review of the existing evidence. International Journal of Surgery 2013;11(3):209-217 PubMed Systematic review

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 25 July 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Serratiopeptidase 120,000”, https://compoatlas.com/en/supplements/canada/80079432-serratiopeptidase-120-000, updated 14 August 2017.

Enter to analyse, Shift+Enter for a new line